Browse GCN1

Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Associates with ribosomes in undifferentiated neuroblastoma cells and increases after neuronal differentiation.
Domain -
Function

Acts as a positive activator of the EIF2AK4/GCN2 protein kinase activity in response to amino acid starvation. Forms a complex with EIF2AK4/GCN2 on translating ribosomes; during this process, GCN1 seems to act as a chaperone to facilitate delivery of uncharged tRNAs that enter the A site of ribosomes to the tRNA-binding domain of EIF2AK4/GCN2, and hence stimulating EIF2AK4/GCN2 kinase activity. Participates in the repression of global protein synthesis and in gene-specific mRNA translation activation, such as the transcriptional activator ATF4, by promoting the EIF2AK4/GCN2-mediated phosphorylation of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52', and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion.

> Gene Ontology
 
Biological Process GO:0006417 regulation of translation
GO:0009267 cellular response to starvation
GO:0009991 response to extracellular stimulus
GO:0010608 posttranscriptional regulation of gene expression
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0033674 positive regulation of kinase activity
GO:0034198 cellular response to amino acid starvation
GO:0034248 regulation of cellular amide metabolic process
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress
GO:0042594 response to starvation
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0071496 cellular response to external stimulus
GO:1990253 cellular response to leucine starvation
Molecular Function GO:0008135 translation factor activity, RNA binding
GO:0019207 kinase regulator activity
GO:0019887 protein kinase regulator activity
GO:0043021 ribonucleoprotein complex binding
GO:0043022 ribosome binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005840 ribosome
GO:0005844 polysome
GO:0005913 cell-cell adherens junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GCN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GCN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GCN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2640.85
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0710.579
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0990.203
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GCN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.52.715.80.0147
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.53.415.10.0291
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GCN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GCN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GCN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GCN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GCN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GCN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGCN1
NameGCN1 eIF2 alpha kinase activator homolog
Aliases KIAA0219; GCN1L; GCN1L1; GCN1 (general control of amino-acid synthesis 1, yeast)-like 1; GCN1 general contro ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GCN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.